Agents and Actions

, Volume 32, Issue 3–4, pp 182–187 | Cite as

Comparative effects of two potentiating peptides (KPP and BPP9a) on kinin-induced rat paw edema

  • P. D. Fernandes
  • J. A. Guimarães
  • J. Assreuy
Allergy, Histamine and Kinins


We have previously shown that KPP, a kinin potentiating peptide generated by tryptic digestion of human plasma proteins potentiated kinin effects on isolated smooth muscle preparations like guinea-pig ileum with high potency and specificity. We also obtained evidence suggesting that, unlike other potentiating peptides, KPP exerts its effect by a mechanism different from the inhibition of kinin metabolism by angiotensin converting enzyme, neutral endopeptidase and kininase I. Here we show the potentiating effect of KPP and of BPP9a, a potentiator derived from snake venom, towards the rat paw edema induced by bradykinin (BK). Our results show that: a) KPP is 25-fold more active than BPP9a in potentiating rat paw edema elicited by BK; b) like BPP9a, KPP is specific in potentiating kinin-induced edema, being ineffective in potentiating edema induced by histamine or serotonin; and c) DesArg9-BK (DABK) elicits a small edematogenic response which can be potentiated by both KPP and BPP9a.


Peptide Serotonin Angiotensin Histamine Angiotensin Converting Enzyme 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    F. Marceau, A. Lussier, D. Regoli and J. P. Giroud,Pharmacology of the kinins: their relevance to tissue injury and inflammation. Gen. Pharmacol.14, 209–229 (1983).PubMedGoogle Scholar
  2. [2]
    D. Regoli and J. Barabé,Pharmacology of bradykinin and related kinins. Pharmacol. Rev.32, 1–16 (1980).PubMedGoogle Scholar
  3. [3]
    E. G. Erdos,Kininases. InBradykinin, Kallidin and Kallikrein. (Ed. E.G. Erdos) Handbook of Experimental Pharmacology, vol. 25 suppl. pp. 428, Springer, Berlin (1979).Google Scholar
  4. [4]
    S. H. Ferreira, D. C. Bartelt and L. J. Greene,Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry9, 2583–2593 (1970).CrossRefPubMedGoogle Scholar
  5. [5]
    M. J. Antonaccio and D. W. Cushman,Drugs inhibiting the renin-angiotensin system. Federation Proc.40, 2275–2284 (1981).Google Scholar
  6. [6]
    S. Maruyama, K. Nakagomi, T. Tomizuka and H. Suzuki,Angiotensin I-converting enzyme inhibitor derived from an enzymatic hydrolysate of casein. II. Isolation and bradykinin-potentiating activity on the uterus and ileum of rats. Agric. Biol. Chem.49, 1405–1409 (1985).Google Scholar
  7. [7]
    B. Blomback, M. Blomback, P. Edman and B. Hessel,Human fibrinopeptides: isolation, characterization and structure. Biochem. Biophys. Acta115, 371–377 (1966).PubMedGoogle Scholar
  8. [8]
    J. G. R. Ufkes, P. N. Aarsen and C. van der Meer,The mechanism of action of two bradykinin-potentiating peptides on isolated smooth muscle. Eur. J. Pharmacol.44, 89–97 (1977).CrossRefPubMedGoogle Scholar
  9. [9]
    J. M. Stewart,Chemistry and biological activity of peptides related to bradykinin. InBradykinin, Kallidin and Kallikrein. (Ed. E. G. Erdos) Handbook of Experimental Pharmacology, vol. 25 suppl. pp. 227, Springer, Berlin (1979).Google Scholar
  10. [10]
    J. Assreuy, A. A. Almeida and J. A. Guimaraes,Characterization of a new kinin potentiating peptide obtained from human plasma proteins. Braz. J. Med. Biol. Res.21, 453–455 (1988).PubMedGoogle Scholar
  11. [11]
    J. Assreuy, A. A. Almeida and J. A. Guimaraes,Pharmacological properties of a new kinin-potentiating peptide generated from human serum proteins. Eur. J. Pharmacol.168, 231–237 (1989).CrossRefPubMedGoogle Scholar
  12. [12]
    S. H. Ferreira,A new method for measuring variations of rat paw volume. J. Pharmacol.31, 648p (1979).Google Scholar
  13. [13]
    A. M. Rothschild,Some pharmacodynamic properties of cellulose sulphate, a kinin-depleting agent in the rat. Br. J. Pharmac. Chemother.33, 501–512 (1968).Google Scholar
  14. [14]
    J. Garcia Leme,Bradykinin System. InInflammation. (Eds.) J. R. Vane and S. H. Ferreira), Handbook of Experimental Pharmacology, vol. 50/1 pp. 464, Springer, Berlin (1978).Google Scholar
  15. [15]
    J. A. Guimaraes and A. Voos,Properties of a kinin potentiating peptide generated in kininogen-depleted human plasma. Agents and Actions9, 295–300 (1982).Google Scholar
  16. [16]
    M. Baggiolini,Phagocyte activation and its modulation by drugs. InThe Pharmacology of Inflammation. (Eds. I. L. Bonta, M. A. Bray and M. J. Parnham) Handbook of Inflammation, vol. 5 pp. 117, Elsevier, Amsterdam (1985).Google Scholar

Copyright information

© Birkhäuser Verlag 1991

Authors and Affiliations

  • P. D. Fernandes
    • 1
  • J. A. Guimarães
    • 1
  • J. Assreuy
    • 1
  1. 1.Departamento de Farmacologia Básica e Clínica, Instituto de Ciências Biomédicas/Centro de Ciências da SaúdeUniversidade Federal do Rio de JaneiroRio de JaneiroBrasil

Personalised recommendations